Common Practice Dilemmas in the Age of Second-Generation Therapy

Common Practice Dilemmas in the Age of Second-Generation Therapy

Please CLICK HERE [https://ce.paradigmmc.com/a/NDTBUV] (www.paradigmmc.com/1401) to review the CME information and complete the pretest for this activity. * (00:00) - Intro * (00:46) - The Current Clinic Capacity Crisis * (07:24) - The Impact of Second Generation Treatments on Patients, Caregivers, and Retina Practices * (15:41) - What Are We Seeing in Clinical Practice * (25:01) - Home OCT and Future Treatment Protocols Treatment paradigms are shifting with the advent of second-generation therapies (eg, faricimab and aflibercept 8 mg) for retinal vascular disease. How will this affect your practice? Listen to renowned experts as they share their own experiences with second-generation therapies and discuss related innovations, clinical challenges, and practical solutions (eg, optical coherence tomography monitoring, the role of biomarkers, and patient engagement) in this lively podcast activity. When you are finished, please CLICK HERE [https://ce.paradigmmc.com/a/NDTBUV] (www.paradigmmc.com/1401) to complete the posttest and evaluation. TRANSCRIPT [https://phc87.paradigmmc.com/retinaunplugged-1/resources/a1402-transcript.pdf] REFERENCES [https://phc87.paradigmmc.com/retinaunplugged-1/references.php]